Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

pharmafile | February 15, 2021 | News story | Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg 

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 million.

The partnership is due to last four years and will work across psoriatic arthritis, rheumatoid arthritis, fibrosis, and vasculitis. The two groups of researchers are combining their forces in the hope of discovering the next generation of drug targets for immunological diseases like those above.

It will be led by the University of Glasgow’s Institute of Infection, Immunity, and Inflammation.

Rheumatoid arthritis alone affects up to 78 million people worldwide, 1% of the global population. It is estimated that within 10 years of diagnosis, 40% of those affected are unable to stay in full-time work, costing the UK alone an average of £700 million a year.

Professor Carl Goodyear, Professor of Translational Immunology, and Leader of the University of Glasgow said: “This is a highly unique collaboration that is aimed at harnessing not only cross-disease comparison but also intra-disease pathological comparison across different affected tissues. By providing this disease and tissue contextualisation it will enable the identification and validation of unique therapeutic targets.”

Professor Iain McInnes, Vice Principal and Head of the College of Medical, Veterinary, and Life Sciences at the University of Glasgow, added: “In the current COVID environment, it is particularly important that our research continues to focus on discovering new ways to treat patients with other diseases that can and will affect people’s quality-of-life.”

Dr Ajay Nirula, Vice President of Immunology at Lilly, commented: “Lilly’s research efforts continue to expand beyond our own laboratories to include unique partnerships with top academic institutions such as the University of Glasgow.

“We look forward to collaborating closely with the scientific team at Glasgow to discover potential new therapies for immunological disorders.”

Jack Goddard

Related Content

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an …


Eli Lilly shares data from two phase 3 tirzepatide studies

Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients …


Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed …

Latest content